1. Introduction {#sec1}
===============

During childhood and adolescence, bone continues to grow until a peak height and peak bone mass are achieved. It is during these periods that children are most vulnerable to interference to skeletal growth, and disturbance to the growing skeleton results from disruption to the processes of endochondral ossification and/or bone remodeling, which may predispose children to earlier onset of skeletal defects. Due to significant advancements and higher survival rate, cancer chemotherapy has been gaining popularity in treatment of paediatric cancers and has become an important risk factor for bone growth defects in paediatric cancer patients. Intensive chemotherapy for childhood cancers has been shown to cause bone growth defects (bone loss, osteopenia, and fractures).

Methotrexate is the most commonly used antimetabolite in childhood oncology, and both clinical and experimental studies have demonstrated methotrexate-induced bone growth impairment. This paper reviews previous studies in which rat models of methotrexate chemotherapy have been used to investigate chemotherapy-induced bone defects, mechanisms of bone growth arrest and bone loss, and recovery potential.

2. Bone Growth and Regulation {#sec2}
=============================

Bone growth is the process involving fascinating changes in morphology and biochemistry during development and growth, which gradually ceases until adolescence ends. During bone growth in childhood and adolescence, lengthening of long bones depends on the process of endochondral ossification, in which the growth plate cartilage continues to produce calcified cartilage which serves as a template for formation of primary trabecular bone \[[@B1]\]. Growth plate is situated at both ends of long bones, which is composed of three distinct zones: the resting, proliferative, and hypertrophic zones. Bone growth begins as progenitor cells at resting zone are activated and enter the cell cycle at the proliferative zone \[[@B2]\] and produce extracellular matrix rich in collagen-II and aggrecan \[[@B1]\]. The hypertrophic chondrocytes secrete matrix rich in collagen-X and direct mineralisation of their surrounding matrix while undergoing apoptosis \[[@B3]\]. Metaphyseal primary bone formation begins as blood vessels invade the mineralised hypertrophic cartilage, which brings in two cell types (osteoblasts and osteoclasts) that remodel the mineralized cartilage to primary woven bone \[[@B1]\]. While osteoclasts resorb the calcified cartilage, osteoblasts penetrate the invaded calcified cartilage and replace it with spongy bone \[[@B1]\]. Bone lengthens as growth plate cartilage continues to grow and is replaced by bone. Longitudinal bone growth is mainly regulated by genetic and hormonal factors such as growth hormone (GH), insulin-like growth factors (IGFs) \[[@B4], [@B5]\], thyroid hormone and glucocorticoids, sex steroids \[[@B6]--[@B8]\], fibroblast growth factors (FGF), epidermal growth factor and related ligands \[[@B9]\] transforming growth factor *β* (TGF-*β*), and bone morphogenic protein (BMP) \[[@B10], [@B11]\]. However, environmental factors such as nutrition \[[@B12]--[@B14]\] and medical treatments including chemotherapy have also been shown to be important determinants for bone growth in children, influencing the final height and bone mass of an individual.

3. The Clinical Issue of Methotrexate-Induced Skeletal Defects {#sec3}
==============================================================

Cancer chemotherapy has been achieving better success in treatment of paediatric cancers, with a survival rate over 80% in treating acute lymphoblastic leukaemia (ALL) which is the major childhood cancer. Consequently, childhood chemotherapy has become an important risk factor for bone growth defects in paediatric cancer patients. Methotrexate (MTX) is the most widely used antimetabolite in the treatment of childhood cancers and is critical for treating acute lymphoblastic leukemia (ALL) \[[@B15]\]. MTX is a folate antagonist, commonly used at high-doses for the treatment of malignancies (100--1,000 mg/m^2^) \[[@B16], [@B17]\] and at lower doses (5--25 mg/week) for the treatment of inflammatory diseases such as rheumatoid arthritis (RA) \[[@B17], [@B18]\]. Frequently reported adverse effects associated with high-dose MTX include nausea, abdominal distress, intestinal mucositis \[[@B19]\], leucopenia, and bone marrow suppression \[[@B20]\]. High-dose MTX has also been shown to have significant damaging effects on bone growth in children \[[@B21]\].

Clinical studies have highlighted osteopenia as a complication for childhood malignancies, characterised by reduced BMD and increased fracture risks \[[@B21], [@B22]\]. During intensive chemotherapy, children treated with high-dose MTX in combination with corticosteroids showed depressed bone formation and enhanced bone resorption \[[@B23], [@B24]\]. On the other hand, some studies reported no significant BMD reduction in survivors of ALL \[[@B25]\]. Since ALL treatment regimens are multiple drug combination therapies with or without cranial irradiation, it is difficult to determine the effects of high-dose MTX alone on bone growth. However, high-doses of MTX and corticosteroid together were found to be associated with longitudinal growth arrest \[[@B26], [@B27]\], a high risk of low bone mass and failure for BMD recovery even after discontinuation of treatment \[[@B25]\]. Overall, the use of high-dose MTX in treating paediatric ALL is encouraged; however, early onset of skeletal complications must be monitored.

4. Mechanistic Studies on MTX Skeletal Defects with Animal Models {#sec4}
=================================================================

The mechanism of how childhood cancer chemotherapy affects bone growth remains largely unknown. Since all ALL treatment protocols vary not only in dosage but also, route of administration and use of cranial irradiation, it is difficult to distinguish the effects of individual chemotherapeutic agents on bone growth. Hence, many laboratory studies have been conducted which have enabled investigations into the effects and underlying mechanisms of different chemotherapeutic agents alone on bone growth. For example, in a rat chemotherapy model, doxorubicin, an anthracycline antibiotic and cytotoxic (antineoplastic) agent commonly used against various cancers, caused thinning of growth plate, disturbance of chondrocyte columnar arrangement, increased number of fat cells but decreased hematopoietic cellularity in the bone marrow \[[@B28]\]. Similarly, *in vitro* studies using human bone marrow cells have shown that corticosteriods (commonly used for treating ALL) can significantly suppress osteoblastic activity, resulting in decreased bone formation \[[@B29]\]. Corticosteroid-induced osteopenia/osteoporosis has been confirmed in animal models \[[@B30]\], has been shown to reduce bone mineral density, and is associated with increased fracture risks in children \[[@B31]\]. In this section, animal studies investigating the mechanisms for MTX-induced skeletal damage are reviewed.

4.1. Methotrexate Chemotherapy-Induced Growth Plate Dysfunction {#sec4.1}
---------------------------------------------------------------

As bone lengthening is the result of endochondral ossification at the growth plate, chemotherapy-induced growth plate damage may impact on bone lengthening. An earlier *in vitro* study examining effects of chemotherapeutic agents on chondrocyte proliferation observed no effects of MTX on proliferating chondrocytes \[[@B32]\]. In a rat study, MTX at 60 mg/m^2^ body surface area (injections once weekly given for 8 weeks) was shown to have no effects on proliferating chondrocytes but to cause an increase in hypertrophic zone thickness and number of hypertrophic chondrocytes \[[@B33]\]. More recent animal studies revealed that while long-term low-dose MTX treatment caused no damage to the growth plate, two cycles of high-dose MTX (at 0.75 mg/kg, 5 days on/9 days off/5 days on) caused a significant decrease in growth plate height \[[@B34]\] ([Figure 1](#fig1){ref-type="fig"}), which was due to the reduction of chondrocyte proliferation ([Figure 1](#fig1){ref-type="fig"}) and collagen-II production, as well as the induction of chondrocyte apoptosis possibly through the Fas/FasL death receptor pathway \[[@B35]\] ([Figure 1](#fig1){ref-type="fig"}). Due to the growth plate dysfunction, a significant reduction in the thickness of newly formed primary spongiosa bone was also found in the adjacent metaphyseal bone, mirroring the thinning of the growth plate \[[@B35], [@B36]\]. These studies suggest that the effect of MTX on growth plate structure and function is largely dependent on the treatment dose and regimen.

4.2. Damaging Effects of Methotrexate Chemotherapy on Osteoblasts, Osteoprogenitors, and Stem Cells {#sec4.2}
---------------------------------------------------------------------------------------------------

High-dose MTX (100--1000 mg/m^2^) acts by reversibly inhibiting the enzyme dihydrofolate-reductase (DHFR). DHFR is essential for the synthesis of purine and thymidylate, thus inhibition of DHFR can ultimately inhibit DNA synthesis and therefore cell proliferation \[[@B17]\]. Osteoblast number and function are important indicators of bone formation and bone mass. Earlier studies which analysed the effects of MTX chemotherapy on bone metabolism revealed that MTX has an inhibitory effect on osteoblast function without altering osteoblast numbers *in vivo*\[[@B37]\]. Another study demonstrated that MTX-induced osteoblastic damage led to a diminished mineralizing surface, mineral apposition rate, and bone formation rate \[[@B38]\]. Consistently, an *in vitro* study using mouse osteoblasts in culture showed that MTX can decrease osteoblastic cell function in a dose-dependent manner, as indicated by a reduction of matrix calcification and supernatant osteocalcin levels \[[@B39]\]. Although earlier studies found no obvious changes in osteoblast density after MTX treatment in rats, more recent studies reported that both acute high-dose and chronic low-dose MTX treatment in rats can reduce osteoblast density on trabecular bone surface \[[@B34], [@B36]\].

Osteoblasts are derived from stromal progenitor cells or mesenchymal stem cells (MSCs), which can differentiate into osteogenic, chondrogenic, or adipogenic cells \[[@B40]\] ([Figure 2](#fig2){ref-type="fig"}). The osteogenic ability of these cells makes it possible to study the toxicity of chemotherapy alone on bone marrow osteoprogenitor cell population and their osteogenic potential. Previously, high-dose chemotherapy (in absence of irradiation) was found to have a direct effect on the stromal population in patients undergoing chemotherapy, caused depletion of bone marrow progenitor cells \[[@B41]\], and resulted in decreased osteoblast differentiation and bone formation \[[@B41], [@B42]\]. Recently, rat models of MTX chemotherapy also demonstrated a reduction in bone marrow osteoprogenitor cells and suppressed stromal progenitor cell proliferation \[[@B34], [@B36]\]. These *in vivo* studies suggest that chemotherapy with several drugs in combination or with MTX alone impairs the oestrogenic commitment of the bone marrow progenitor cell population, the severity and recovery of which are major determinants of the extent of bone loss and recovery potential following chemotherapy.

*In vitro* studies found that human bone marrow MSCs appear more resistant to MTX, cyclophosphomide and busulphan than peripheral blood mononuclear cells \[[@B43]\], and that isolated MSCs from normal or chemotherapy-exposed patients remain unaffected by the presence of cytotoxic agents in culture when assessed for differentiation or proliferative potential \[[@B44]\]. These studies suggest that while the already committed osteoprogenitor cells can be more easily affected by chemotherapy drugs, the quiescent MSCs appear to have the capacity to maintain their number and their stem cell character both *in vivo* and *in vitro* in response to some chemotherapeutic agents \[[@B44]\]. This perhaps explains why the bone and bone marrow stroma can regenerate in the MTX acute treatment models in rats \[[@B34]--[@B36]\].

4.3. Methotrexate Chemotherapy-Induced Marrow Adiposity {#sec4.3}
-------------------------------------------------------

In recent rat studies of MTX chemotherapy-induced bone defects, it has been found that apart from the reduced osteoblast number and trabecular bone volume, there is a significant increase in marrow adiposity \[[@B35], [@B36]\] ([Figure 2](#fig2){ref-type="fig"}). Consistently, one early *in vitro* study demonstrated that the presence of MTX can significantly increase the number of fat-containing cells in bone marrow culture \[[@B45]\]. These studies suggest that MTX chemotherapy can cause a reciprocal switch in bone versus fat volume in the bone marrow microenvironment. Since adipocytes and osteoblasts share a common precursor (bone marrow MSC), it has been proposed that bone loss may result from a switch in favour of adipocyte differentiation over osteoblast commitment. Since the Wnt signalling pathway stimulates osteoblast lineage commitment and inhibits adipocyte formation \[[@B46], [@B47]\], it is of interest to examine whether deregulation of Wnt signaling may be involved in this bone/fat reciprocal relationship following MTX chemotherapy.

4.4. Effects of Methotrexate on Haematopoietic Cells and Osteoclast Formation {#sec4.4}
-----------------------------------------------------------------------------

In addition to the damage to osteoblasts, bone marrow stromal cells (discussed above), haematopoietic stem cells (HSCs), and haematopoiesis \[[@B48]\], another possible mechanism for chemotherapy-induced decrease in bone mass in children is the increased formation of bone resorptive cells (osteoclasts) and the alteration to the bone remodeling balance in favour of bone resorption. Clinically, children undertaking high-dose MTX treatment have lower bone mass, with increased urinary and faecal calcium excretion, suggesting increased bone resorption \[[@B24], [@B49]\]. Results from both short- and long-term rat studies revealed that MTX can cause an increase in osteoclast density on trabecular bone surface \[[@B34], [@B38], [@B50]\] ([Figure 3](#fig3){ref-type="fig"}). Similarly, an increase in the number of empty Howship lacunae on the trabecular surface \[[@B51]\] and excretion of hydroxyproline \[[@B50]\] following MTX administration are evident in animal studies which further support the argument of increased bone resorption. A recent *ex vivo* study using bone marrow cells obtained from rats treated with MTX showed an increase in the osteoclast precursor cell pool which express surface marker CD11b^+^ and an increase in *ex vivo* osteoclast formation \[[@B34]\] ([Figure 3](#fig3){ref-type="fig"}). Mac-1 (CD11b/CD18) has been shown to play a role in facilitating the differentiation of osteoclast precursors into mature osteoclasts when stimulated by the key osteoclastogenic cytokine RANKL \[[@B52]\]. Collectively, this indicates that MTX chemotherapy affects osteoclastogenesis at the precursor level.

Some clinical data revealed an increased serum level of proinflammatory cytokine TNF-*α* in patients undergoing chemotherapy \[[@B53]\], suggests a potential role for proinflammatory cytokines in chemotherapy-induced osteoclastogenesis. It is known that, apart from RANKL, osteoclast differentiation and activity can be enhanced by proinflammatory mediators such as IL-1, IL-6, and TNF-*α* \[[@B54]\]. Whilst increased precursor and mature osteoclast presence within the bone strongly suggests increased resorptive activity, no animal studies have directly investigated this link in chemotherapy model. Future studies are required to investigate the potential role of proinflammatory cytokines in osteoclastogenesis as well as the mechanisms by which MTX chemotherapy may induce an inflammatory response within the bone marrow microenvironment.

5. Conclusions and Future Perspectives {#sec5}
======================================

As longitudinal bone growth occurs during childhood and adolescence, altered bone metabolism during this period may interfere with bone growth and bone mass accrual, which may result in lower peak bone mass, potentially leading to premature onset of osteopenia and increased fracture risk \[[@B55]\]. The advancement and success of chemotherapy in treating childhood cancers (particularly ALL) and thus its increasing use in paediatric oncology have resulted in a growing population of young cancer survivors with increased bone health risks (reduced bone growth and lower peak bone mass). Although the mechanism for chemotherapy-induced bone damage is multifactorial, recent research has revealed that chemotherapeutic agents can directly impair bone growth. In particular, rat studies have confirmed that MTX can directly disrupt the growth plate structure and function by inducing chondrocyte apoptosis. reducing chondrocyte proliferation and cartilage protein synthesis. Dysfunction of the growth plate, therefore, reduces formation of primary woven bone. Direct damage to osteoblasts by decreasing osteoblast activity/formation (possibly through inducing the switch in the bone marrow stromal cells towards adipogenic differentiation at the expense of osteogenesis) and bone marrow osteoprogenitor cells also contributes to reduced bone formation. In addition, MTX chemotherapy has also been shown to increase osteoclast formation and cause aggravated bone resorption, contributing to the associated bone loss.

Given the increased rates of fractures and early onset of osteopenia in childhood survivors of ALL, future studies should investigate strategies to reduce skeletal toxicities and improve quality of life of chemotherapy patients. Currently, recommendations and therapeutic strategies for reducing childhood bone loss during chemotherapy are limited, and there have been few studies investigating potential adjuvant treatments to reduce chemotherapy-induced skeletal toxicities. In this context, the rat models of MTX chemotherapy have also been shown to be useful in demonstrating that folinic acid, an antidote used clinically to reduce toxicity to soft tissues such as gut and bone marrow haematopoietic cells, is also efficacious to reduce or prevent MTX chemotherapy-induced bone growth defects \[[@B34]\].

![Effect of acute high-dose MTX chemotherapy on growth plate structure and cellular changes in young rats. H & E stained section of a normal rat tibial growth plate (a) and an MTX-treated rat growth plate (b). Dashed line represents total heights of growth plates. BrdU labeling showing proliferative chondrocytes in a normal rat (c) and an MTX-treated rat (d), with arrows pointing to proliferating chondrocytes. Normal proliferative/hypertrophic chondrocytes of a normal rat (e) showing no apoptosis; MTX-treated rats with apoptotic chondrocytes in lower proliferative/upper hypertrophic zone (f), and a magnified view of apoptotic chondrocyte (g). (Images are from the authors\' own lab and have not been published previously.)](JBB2011-903097.001){#fig1}

![Mesenchymal stem cell commitment and effects of MTX chemotherapy in bone marrow adiposity. Multipotency of the mesenchymal stem cell (a), illustrated by the capacity to differentiate down a number of cell lineages. H & E stained bone marrow section taken from a control rat (b) and from an acute high-dose MTX-treated rat (c) showing adipocyte-rich bone marrow. (Images are from the authors\' own lab and have not been published previously.)](JBB2011-903097.002){#fig2}

![Effect of MTX chemotherapy on osteoclast density in young rats. H & E stained sections showing osteoclasts along trabecular bone surface in a control rat (a) and an MTX-treated rat (b), with arrows pointing to multinucleated osteoclasts. TRAP-stained osteoclasts formed *ex vivo* from bone marrow cells of a control rat (c) and an MTX-treated rat (d), with arrows pointing to multinucleated TRAP^+^ osteoclasts. (Images are from the authors\' own lab and have not been published previously.)](JBB2011-903097.003){#fig3}
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